Nurix Therapeutics (NASDAQ: NRIX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-07-15 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.880 | -0.950 | -0.0700 | ||||
REV | 9.270M | 9.621M | 351.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Nurix Therapeutics (NASDAQ: NRIX) through any online brokerage.
Other companies in Nurix Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Kezar Life Sciences (NASDAQ:KZR), Cogent Biosciences (NASDAQ:COGT), Eagle Pharmaceuticals (NASDAQ:EGRX) and Altimmune (NASDAQ:ALT).
The latest price target for Nurix Therapeutics (NASDAQ: NRIX) was reported by Wells Fargo on Tuesday, May 31, 2022. The analyst firm set a price target for 25.00 expecting NRIX to rise to within 12 months (a possible 87.69% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Nurix Therapeutics (NASDAQ: NRIX) is $13.32 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Nurix Therapeutics.
Nurix Therapeutics’s Q2 earnings are confirmed for Friday, July 15, 2022.
There is no upcoming split for Nurix Therapeutics.
Nurix Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.